Ponesimod
Ponesimod (Ponvory) is an oral medication used to treat relapsing forms of multiple sclerosis in adults.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 2 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Ponesimod: Patient Information Guide
A plain-language walkthrough of Ponesimod — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Ponesimod is approved for adults with relapsing forms of multiple sclerosis (MS).
- Ponvory (oral tablet) is indicated for relapsing-remitting MS — the most common form, marked by flare-ups followed by recovery periods
- Ponvory is also approved for clinically isolated syndrome (CIS) — a first episode of neurological symptoms that may signal MS
- Ponvory is approved for active secondary progressive MS — a later stage where disability gradually worsens but relapses are still occurring
⚙️How it works▾
Ponesimod latches onto a receptor called sphingosine 1-phosphate receptor 1 (S1P receptor 1) found on certain immune cells called lymphocytes. By activating this receptor, it traps lymphocytes inside lymph nodes rather than letting them circulate in the blood. With fewer of these immune cells traveling through the body, there may be less immune-driven damage to the brain and spinal cord — though the precise mechanism behind its MS benefit is not fully established.
Importantly, this effect is reversible. When you stop taking ponesimod, lymphocyte counts generally return to the normal range within 1 to 2 weeks.
💊How it's taken▾
Ponvory is taken orally once daily as a tablet, with or without food. Treatment must begin with a gradual 14-day titration (step-up) schedule using a starter pack; only after completing this ramp-up does the regular daily maintenance dose begin on Day 15 and beyond.
- Swallow Ponvory tablets whole — do not crush or chew
- Try to take it at the same time each day
- If you miss fewer than 4 doses in a row, resume where you left off in the titration or continue your maintenance dose
- If you miss 4 or more doses in a row during titration or maintenance, you must restart from Day 1 of the titration with a new starter pack — talk to your doctor right away
🤒Side effects — in detail▾
The most common side effects with Ponvory (occurring in at least 10% of patients in clinical trials) were upper respiratory infections, elevated liver enzymes, and high blood pressure.
- Upper respiratory tract infections (colds, pharyngitis, bronchitis)
- Elevated liver enzymes (hepatic transaminase elevation)
- High blood pressure (hypertension)
- Urinary tract infection
- Shortness of breath (dyspnea)
- Dizziness
- Cough
- Slow heart rate (bradycardia), especially when starting treatment
Serious reactions to act on immediately include signs of infection, vision changes, significant slowing of the heartbeat, chest discomfort, yellowing of the skin or eyes, or any new neurological symptoms such as sudden weakness or confusion.
⚠️Warnings & precautions▾
- Heart rate slowing: Ponvory can cause a temporary drop in heart rate — especially with the first dose. A 14-day titration is required, and some patients need heart monitoring (ECG and pulse checks) during initiation. Patients with certain heart conditions must not take Ponvory at all.
- Serious infections: Because Ponvory lowers the number of circulating immune cells, your infection risk goes up. Rare but life-threatening infections — including a brain infection called PML (progressive multifocal leukoencephalopathy), cryptococcal meningitis, and herpes viral infections — have been reported with this class of drug. Stay alert for fever, unusual fatigue, or new neurological symptoms.
- Liver injury: Ponvory can cause liver enzyme elevations; liver function should be checked before starting and monitored during use.
- Eye problems: Macular edema (swelling in the center of the retina that can blur vision) is a known risk. A baseline eye exam is recommended, and you should report any vision changes promptly.
- Fetal harm: Animal studies showed serious birth defects. Women who can become pregnant must use reliable contraception during treatment and for at least 1 week after stopping.
- Skin cancers: Cases of basal cell carcinoma and melanoma have been reported. A skin exam is recommended before or shortly after starting, with periodic checks during treatment.
- Stopping the medication: Do not stop Ponvory without talking to your doctor — there is a risk of a severe return of MS symptoms after discontinuation, and immune effects can persist for 1–2 weeks.
🔀What it interacts with▾
Ponvory can interact with several types of medications — always tell your doctor and pharmacist everything you take.
- Beta-blockers (e.g., propranolol): Adding Ponvory to a beta-blocker can amplify heart rate slowing; temporary interruption of the beta-blocker may be needed at the start of Ponvory
- Heart rate-slowing calcium channel blockers (verapamil, diltiazem) or digoxin: Increased risk of severe heart slowing — generally avoid starting Ponvory together with these drugs
- Class Ia or III anti-arrhythmic drugs (e.g., amiodarone, sotalol, quinidine, procainamide): Risk of serious heart rhythm problems (torsades de pointes); cardiology advice is needed before combining
- Strong CYP3A4 and UGT1A1 inducers (e.g., rifampin, phenytoin, carbamazepine): May reduce ponesimod levels in the body; combination is not recommended
- Immunosuppressants and immune-modulating therapies: Additive immune suppression; use with caution and inform your doctor of all current or recent MS treatments
- Live attenuated vaccines: Avoid during Ponvory treatment and for 1–2 weeks after stopping; all vaccines may be less effective while on Ponvory
- Alemtuzumab: Starting Ponvory after alemtuzumab is not recommended due to prolonged immune-suppressive overlap
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Do not take Ponvory if you have had a heart attack, unstable angina, stroke, TIA, or hospitalization for heart failure in the past 6 months
- Do not take Ponvory if you have Mobitz type II second-degree AV block, third-degree AV block, sick sinus syndrome, or sino-atrial block — unless you have a functioning pacemaker
- Tell your doctor about any heart rhythm disorder, history of fainting, or use of heart-rate-lowering medications
- Ponvory is not recommended for people with moderate or severe liver impairment (Child-Pugh class B or C)
- Get your varicella (chickenpox) immune status checked before starting; if you have not been vaccinated, you may need the vaccine at least 4 weeks before beginning Ponvory
- Pregnancy: Animal data showed serious fetal malformations; women of childbearing potential must use effective contraception during and for at least 1 week after treatment
- Breastfeeding: It is unknown whether ponesimod passes into human breast milk; discuss the risks and benefits with your doctor
- Children: Safety and effectiveness have not been established in pediatric patients
- Older adults (65+): Use with extra caution; clinical trials did not include patients 65 and older, and age-related heart, liver, or kidney changes may affect how this drug is tolerated
- Tell your doctor about all immunosuppressant or immune-modulating medications you have taken, including recently discontinued ones
🚑If you take too much▾
If too much Ponvory is taken — especially during the titration phase — the most important risks are a dangerously slow heart rate and heart conduction blocks. There is no specific antidote, and dialysis will not meaningfully remove ponesimod from the body because it binds so tightly to blood proteins.
If an overdose is suspected, stop the medication, seek emergency care immediately, and call a poison control center. Medical staff can monitor heart rate and blood pressure and, if needed, use atropine to help reverse the heart-rate slowing effect.
📡Pharmacodynamics — effects in the body▾
Ponesimod causes a dose-dependent reduction in circulating lymphocytes — a key part of the immune system — by trapping them in lymph nodes. This effect peaks around 6 hours after a dose and affects B cells and T cells (including T-helper and T-cytotoxic cells), though natural killer (NK) cells are not affected. At the start of treatment, Ponvory also temporarily slows heart rate and can delay electrical conduction between the heart's upper and lower chambers; this effect begins within 1 hour of the first dose, peaks at 2–4 hours, and largely returns to normal by 4–5 hours. Ponvory also causes small, dose-dependent reductions in lung function (FEV1 and FVC), which can be reversed with a short-acting bronchodilator.
🔬Pharmacokinetics — how your body processes it▾
After an oral dose, ponesimod is well absorbed, reaching peak blood levels in 2–4 hours, with about 84% of the dose making it into the bloodstream. Food does not meaningfully affect absorption, so Ponvory can be taken with or without a meal. Ponesimod is extensively bound to blood proteins (over 99%) and has an elimination half-life of about 33 hours, meaning it takes roughly 1–2 weeks after stopping for lymphocyte counts to fully recover in most patients. The drug is broken down in the liver through multiple enzyme pathways and eliminated mainly through the stool; no dose adjustment is needed for kidney impairment, but Ponvory should be avoided in moderate to severe liver impairment due to significantly increased drug exposure.
📦How to store it▾
Store at 20ºC to 25ºC (68ºF to 77ºF); excursions permitted from 15ºC to 30ºC (59ºF to 86ºF) . Store in the original package. Protect from moisture.
📄 Written from Ponesimod’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
Supplements & herbs that interact with Ponesimod
146 supplements and herbal products have documented interactions with Ponesimod in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 8
- Moderate · 98
- Minor · 40
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Ponesimod — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly is Ponvory treating — is it curing my MS? ▾
Why do I have to take so many different doses at the start instead of just jumping to my regular dose? ▾
What side effects are most likely, and which ones should make me call my doctor right away? ▾
Can I take my other medications alongside Ponvory? ▾
Is it safe to get pregnant while taking Ponvory? ▾
What happens if I miss a dose or need to stop taking Ponvory? ▾
Is Ponesimod available over the counter? ▾
When was Ponesimod first available? ▾
Who makes Ponesimod? ▾
💬 Answers drafted from Ponesimod’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Ponesimod comes
Ponesimod is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Tablet
How this form is used
- Ponvory is used to treat relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS
- Ponvory tablets should be swallowed whole once daily — do not crush or chew
- Ponvory can be taken with or without food
- Ponvory must be started with a 14-day titration (dose-increase) schedule using a starter pack before reaching the maintenance dose
- If 4 or more consecutive Ponvory doses are missed during titration or maintenance, restart from Day 1 of the titration regimen with a new starter pack
📊 Ponesimod across the U.S. market
How Ponesimod appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Kit (4) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
🔍 Compare Ponesimod products
A representative set of FDA-listed product records for Ponesimod — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| 20 mg | Oral | Janssen Pharmaceuticals, Inc × 3 listings | NDA | View NDC → |
| 2 mg | — | Patheon France S.A.S. | DRUG FOR FURTHER PROCESSING | View NDC → |
| 3 mg | — | Patheon France S.A.S. | DRUG FOR FURTHER PROCESSING | View NDC → |
| 4 mg | — | Patheon France S.A.S. | DRUG FOR FURTHER PROCESSING | View NDC → |
| 5 mg | — | Patheon France S.A.S. | DRUG FOR FURTHER PROCESSING | View NDC → |
| 6 mg | — | Patheon France S.A.S. | DRUG FOR FURTHER PROCESSING | View NDC → |
| 7 mg | — | Patheon France S.A.S. | DRUG FOR FURTHER PROCESSING | View NDC → |
| 8 mg | — | Patheon France S.A.S. | DRUG FOR FURTHER PROCESSING | View NDC → |
| 9 mg | — | Patheon France S.A.S. | DRUG FOR FURTHER PROCESSING | View NDC → |
| 10 mg | — | Patheon France S.A.S. | DRUG FOR FURTHER PROCESSING | View NDC → |
| 20 mg | Oral | Vanda Pharmaceuticals Inc. | NDA | View NDC → |
| 💊Kits | ||||
| — | — | Janssen Pharmaceuticals, Inc × 3 listings | NDA | View NDC → |
| — | — | Vanda Pharmaceuticals Inc. | NDA | View NDC → |
Showing 17 of 17 products — FDA National Drug Code Directory. See every product, package size and price: browse all 17 Ponesimod NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Ponesimod — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Ponesimod in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Ponesimod went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2532300 1 dose form · 10 strengths
-
Dose form (SCDF) Oral Tablet RxCUI 2532304In current FDA listings
Look up RxCUI 2532300 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Ponesimod is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Ponesimod belongs to the Sphingosine 1-phosphate Receptor Modulator class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 2 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Vanda Pharmaceuticals Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.